Advanced glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients

https://doi.org/10.1515/biol-2020-0042
received February 3, 2020; accepted May 3, 2020

Abstract: Diabetes mellitus with atherosclerosis (AS) adds to the social burden. This study aimed to investigate whether advanced glycation end product (AGE) levels were correlated with inflammation and carotid AS (CAS) in type 2 diabetes mellitus (T2DM) patients. A total of 50 elderly T2DM patients and 50 age-matched senior healthy subjects were recruited in this study. T2DM patients were classified into two groups based on the intima–media thickness (IMT) of the carotid artery from color Doppler ultrasonography. Patients with IMT > 1 mm were classified into the T2DM + CAS group (n = 28), and patients with IMT < 1 mm were assigned as the T2DM + non-atherosclerosis (NAS) group (n = 22). The plasma levels of AGEs, receptor for AGE (RAGE), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) of all subjects were measured by enzyme-linked immunosorbent assay.

1 Introduction

Diabetes mellitus is a metabolic disorder characterized by the impaired response to insulin and decreased insulin secretion in the body, resulting in chronic hyperglycemia [1]. Type 2 diabetes mellitus (T2DM) is the most common type of diabetes with a global prevalence of 350 million people in 2014 [2]. The number of T2DM patients is expected to increase significantly in the coming years, posing serious health and economic challenges. T2DM is associated with many long-term complications in the heart, blood vessels, kidney, nerves, and eyes. About 4.9 million people die of diabetes each year, in which around 50% is due to cardiovascular complications [3]. Atherosclerosis (AS) is a common complication of T2DM. Early detection and intervention of AS are of vital significance in the comprehensive management of T2DM. Carotid artery (CA) is the most easily involved blood vessel in AS; and its location is relatively superficial, but the degree and nature of carotid AS (CAS) can reflect the severity of the lesion. AS is actually a chronic inflammatory disease, in which various inflammatory and immune responses are involved. It has been reported that patients with diabetes presented larger necrotic cores in their coronary arteries and enhanced inflammation involved with macrophages and T-lymphocytes compared to patients...
without diabetes [4]. The intima–media thickness (IMT) of CA, defined as the distance from the leading edge of the media–adventitia interface to the leading edge of the lumen–intima interface, has been widely used as an indicator of the level of AS development [5,6].

Increased serum level of advanced glycation end products (AGEs) has been reported in T2DM patients with AS, which suggests its association with the development of vascular complications [7]. AGEs can interact with the receptor for AGEs (RAGEs) to induce inflammation [8,9]. Late glycosylation can induce glycosylation of proteins related to lipid metabolism, leading to lipid function damage and lipid metabolism disorder and eventually vascular complications in diabetes [10,11]. There are different degrees of lymphocyte infiltration in human atherosclerotic plaques. The T cells also play an important role in AS at the early stage, especially the clonal selection and expansion of their subsets [12]. Lymphocyte subsets mainly participate in the formation of AS by secreting cytokines [13,14].

To further understand how AGEs accelerate diabetic AS, we investigated the plasma level of AGEs, RAGE, T-lymphocyte subsets, and inflammatory cytokines including tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) in the peripheral blood of elderly patients with type 2 diabetes. This study was undertaken to observe the effects of AGEs on T-lymphocyte-secreting inflammatory cytokines and to provide new insights for the prevention and treatment of complications of type 2 diabetes.

2 Materials and methods

2.1 Participants

Fifty patients with T2DM (n = 50, male/female: 21/29) were recruited in this study. T2DM was diagnosed based on 1999 World Health Organization criteria: fasting plasma glucose ≥7.0 mmol/L or 2-h plasma glucose ≥11.1 mmol/L. The inclusion criteria were (1) newly diagnosed T2DM patients, from January to August 2018; (2) consistent diet and/or treatment plans for 2 weeks; (3) age between 60 and 70 years; (4) body mass index between 19 and 35 kg/m²; and (5) no symptoms of diabetic ketoacidosis observed in the past 6 months. Patients were excluded according to the following criteria: (1) type 1 diabetes mellitus; (2) clinical signs of acute and/or chronic infection; tumor, hematologic diseases, liver disease, renal dysfunction, cardiovascular, and cerebrovascular diseases; and (3) history of smoking. Fifty healthy elderly participants were also included in this study (n = 50; male/female: 26/24). All healthy subjects showed normal fasting plasma glucose (<6.1 mmol/L), normal 2-h plasma glucose (<7.8 mmol/L), and had no sign of CAS. All the clinical parameters of the recruited subjects are shown in Table A1.

Informed consent: Informed consent has been obtained from all individuals included in this study.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the Ethics Committee of Clinical Research.

2.2 CA ultrasonography

Color Doppler ultrasonography was performed to measure the IMT of CA by using an ultrasound scanner (HP5500; GE, USA) with a linear transducer of 5–10 MHz frequency. Patients were examined at a supine position. The B-mode gray scale images of the common CA, the bulb, the internal carotids, and the external carotids were recorded. The IMT measures the thickness of the two layers of the artery wall, tunica intima, and tunica media. The normal IMT of CA as evaluated by B-mode imaging is less than 1.0 mm. IMT at or above 1 mm is considered to be associated with AS. Based on the results from CA ultrasonography, 50 diabetes patients were divided into two subgroups: (1) T2DM + NAS group (n = 22; male/female: 10/12) with IMT < 1.0 mm and (2) T2DM + CAS group (n = 28; male/female: 11/17) with IMT ≥ 1.0 mm.

2.3 Enzyme-linked immunosorbent assay (ELISA)

Peripheral blood was taken from all subjects following 8 h of fasting. The levels of AGEs, RAGE, TNF-α, and IFN-γ in the peripheral blood were measured by AGEs, RAGE, TNF-α, and IFN-γ ELISA kits (Uscn life, USA), respectively, according to the manufacturer’s protocol.

2.4 T-lymphocyte subset analysis

Fasting peripheral whole blood was collected between 7:00 and 9:00 am. Heparinized peripheral whole blood (400 µL) was diluted into 400 µL RPMI1640 medium, added with 42 µL
1 μg/mL of phorbol myristate acetate, 33 μL 50 μg/mL of ionomycin, and 13.6 μL 0.1 mg/mL monensin (Sigma, Saint Louis, USA) and incubated at 37°C/5% CO₂ for 4.5 h. Then the peripheral blood mononuclear cells (PBMCs) were separated by high-speed refrigerated centrifuge (Eppendorf, Germany). For staining, 100 μL of PBMCs was incubated with PerCP-Cy5.5 conjugated antihuman CD4 monoclonal antibody (clone: OKT4, Cat.: 85-45-0048-42) and antihuman CD25 monoclonal antibodies (clone: BC96, Cat.: 85-17-0259-42), separately. Each lymphocyte subset was collected by a flow cytometer (BD, USA), and the data were analyzed by FlowJo.

2.5 Statistical analysis

Software SPSS (Version 21.0) was used for statistical analysis. All data are reported as mean ± standard deviation and all data are normally distributed. Significant difference between the mean values of two groups was calculated by t test. One-way analysis of variance was used when comparison was among more than two groups. Correlation between AGEs and other clinical indicators was determined by age-adjusted partial correlation coefficient analysis. p < 0.05 was considered to be statistically significant.

3 Results

3.1 T2DM patients with CAS showed significantly higher IMT and elevated plasma levels of AGEs and RAGE

The IMT of CA in the healthy subjects was 0.68 ± 0.16 mm, which was not significantly different from that in the T2DM + NAS group (0.76 ± 0.20 mm). However, in the T2DM + CAS group, their average IMT (1.22 ± 0.21 mm) was significantly higher compared to that in the healthy subjects and the T2DM + NAS group (Figure 1). Plasma levels of AGEs in healthy subjects, T2DM + NAS group, and T2DM + CAS group were 32.85 ± 15.26, 53.47 ± 15.39, and 66.71 ± 16.36 ng/mL, respectively (Figure 2a). Healthy subjects showed significantly lower level of AGEs compared to the other two groups. Plasma level of RAGE was also significantly lower in the control group (0.31 ± 0.11 ng/mL) than that in the T2DM + NAS (0.47 ± 0.17 ng/mL) and T2DM + CAS groups (0.59 ± 0.21 ng/mL; Figure 2b).

3.2 Increased expression levels of TNF-α and IFN-γ were observed in T2DM patients with and without CAS

The expressions of inflammatory cytokines including TNF-α and IFN-γ were significantly higher in the T2DM + NAS and T2DM + CAS groups than those in the control group. The plasma levels of TNF-α were 7.82 ± 1.92, 8.94 ± 2.05, and 14.79 ± 3.15 pg/mL in healthy subjects, T2DM + NAS group, and T2DM + CAS group, respectively (Figure 3a). Meanwhile, the levels of IFN-γ were 1.40 ± 0.53, 1.61 ± 0.51, and 2.11 ± 0.37 pg/mL in the respective three groups (Figure 3b).

3.3 The number of CD4+ T cells was increased in T2DM + CAS patients

Both the T2DM + NAS and T2DM + CAS groups had a significantly larger amount of CD4+ T cells compared to healthy subjects. Moreover, the number of CD4+ T cells in T2DM + NAS patients was significantly higher than that in the T2DM + CAS patients (p < 0.05). The ratio of CD4+/CD8+ was also significantly lower in the healthy groups. In contrast, T2DM + CAS showed the least amount of CD8+ T cells among these groups (Table 1).

3.4 Correlation analysis of AGEs and other clinical indicators

Correlation analysis was performed and the results showed that there was a positive correlation between AGEs and RAGE (Figure 4a), TNF-α (Figure 4b), IFN-γ (Figure 4c), and CD4+ (Figure 4d; P < 0.05). However, it was negatively correlated with CD8+ (Figure 4e) and CD4+ CD25+ (Figure 4f and Table 2).
**Discussion**

AS is a common vascular complication in T2DM [15]. IMT has been widely used as a noninvasive indicator of AS at subclinical stage [16]. Our lab performed color Doppler ultrasonography to measure the IMT of CA in senior T2DM patients. The diagnostic criterion of AS is IMT ≥ 1 mm. Based on the results of IMT, we classified 50 T2DM patients into the T2DM + NAS group (n = 22) with IMT > 1 mm and the T2DM + NAS group (n = 28) with IMT < 1 mm. AGEs can be rapidly cleaned up from blood [17], and the levels of AGEs were low in normal physiological conditions. However, aging or diabetes with high sugar content can accelerate the saccharification process, leading the body to produce AGEs spontaneously. When the generation rate is higher than the degradation rate, it will lead to accumulation of AGEs in the body [18]. AGEs interact with their RAGE to initiate intracellular signaling pathways involving the change in vascular structure and then accelerate the progression of AS [19]. RAGE is a multiligand receptor that belongs to the immunoglobulin superfamily, often seen on the surface of smooth muscle cells, macrophages, T-lymphocytes, glomerular podocytes, and neurons [20].

**Table 1:** Determination of T-cell subsets in peripheral blood

| Grouping    | CD4+ (%) | CD8+ (%) | CD4+/CD8+ (%) | CD4+ CD25+ Treg (%) |
|-------------|----------|----------|---------------|---------------------|
| Control     | 20.58 ± 1.46 | 26.34 ± 1.99 | 0.88 ± 0.12 | 4.10 ± 0.61 |
| T2DM + NAS  | 23.49 ± 2.11<sup>a</sup> | 24.16 ± 2.23<sup>a</sup> | 0.97 ± 0.15<sup>a</sup> | 3.77 ± 0.35<sup>a</sup> |
| T2DM + CAS  | 31.37 ± 2.49<sup>a,b</sup> | 23.05 ± 2.51<sup>a</sup> | 1.35 ± 0.24<sup>a,b</sup> | 3.36 ± 0.34<sup>a,b</sup> |

<sup>a</sup>p < 0.05 compared with the normal control group.  
<sup>b</sup>p < 0.05 compared with the T2DM + NAS group.
studies focused on the effect of AGE-RAGE on reactive oxygen species generation in the process of AS. However, whether AGEs-RAGE interaction causes AS by affecting T lymphocytes remains unknown.

Figure 4: Scatter plots of linear correlation between peripheral blood AGE level and other clinical indicators. Pearson’s correlation coefficient analysis was used to calculate the correlation between peripheral blood AGEs level and RAGE (a), TNF-α (b), IFN-γ (c), CD4+ (d), CD8+ (e), and CD4+ CD25+ (f).
AS is characterized by chronic inflammation. Numerous neutrophils, mononuclear macrophages, and T lymphocytes are found in plaques at various stages of AS, so the relationship between AS and innate immune pattern recognition has been of concern for a long time. Recent studies suggest that AGEs are a molecular pattern related to damage in the body, and RAGE is a pattern recognition receptor. After being recognized by RAGE, AGEs can activate the immune response. From the perspective of immune mechanism, the research on the mechanism of AGE-RAGE reaction promoting the occurrence and development of diabetic AS is a hot spot.

Previously, it has been found that T cells express the receptor of AGEs on the surface, and RAGE with a molecular weight of 50–60 kd is the main one. Imani et al. labeled AGEs with 1125 to observe the binding ability of peripheral lymphocyte surface receptors [21]. It was found that the ability of lymphocyte-binding AGEs significantly increased after 48 h of pre-stimulation of peripheral blood lymphocytes by phytohemagglutinin. CD4+ T cells increased from 34.2% to 92%, while CD8+ T cells increased from 58.5% to 90%, and it was found that peripheral blood lymphocytes expressed IFN-γ up to ten times higher. This suggests that AGE is one of the factors affecting immune disorders of T cells and plays a role in vascular complications of diabetes mellitus.

The major class of T lymphocytes present in AS is CD4+, which can differentiate into Th1 and Th2 cells based on the local milieu of cytokines. The Th1 lineage may be the key regulator of lymphocytic influence in the development of AS [22]. Both Th1 cells and CD8+ T cells can secrete inflammatory cytokines IFN-γ and TNF-α. We found significantly higher levels of AGEs, RAGE, IFN-γ, and TNF-α in the T2DM + CAS group compared with the T2DM + NAS group and controls. It suggested that the increased concentration of AGEs and RAGE in peripheral blood was correlated with the occurrence and development of AS in T2DM. Meanwhile, T2DM + CAS patients also showed imbalanced T cells and decreased Treg cells. Pearson analysis revealed a positive correlation between AGEs and RAGE, CD4+, IFN-γ, and TNF-α, suggesting that combining AGES and RAGE activates the immune response in the body and promotes the secretion of inflammatory factors IFN-γ and TNF-α. Weiser et al. showed that IFN-γ synergized with other cytokines to elevate the expression of the adhesion molecules, vascular cell adhesion molecule-1 in brain endothelial cells [23]. IFN-γ also impaired the cellular cholesterol balance, by reducing the expression of cholesterol 27-hydroxylase, to facilitate the pathogenesis of AS [24]. Another potential mechanism of IFN-γ contributing to the atherosclerotic process was through a p53-dependent DNA damage pathway in cellular senescence [25]. TNF-α is also considered as a key factor involved in AS. Ridker et al. found that the plasma concentration of TNF-α is persistently increased in postmyocardial ischemia patients with higher risk of recurrent coronary events [26]. Treg cells were also reported to have a regulatory effect on the initiation and progression of AS [27]. In this study, senior T2DM + CAS patients showed a lower concentration of CD4+ CD25+ Treg in peripheral blood than that in the healthy subjects. Although no correlation was found between AGEs vs CD8+ and AGES vs Treg, significantly decreased levels of CD8+ T cells and Treg cells were observed in T2DM + CAS patients. It suggests the involvement of CD8+ T cells and Treg cells in AS.

In this study, we would like to address several study limitations. First, the study was performed in a single center, and further studies may involve multicenter so as to increase the power of our current findings. Second, as using IMT as a predictor of cardiovascular risk has been controversial among studies [28], we should carefully interpret our findings and may employ more diagnostic tools to confirm the current findings. Third, conflicting results regarding the role of AGEs in the development of coronary artery disease have been reported [29]; further studies may increase the sample size to confirm our findings. Finally, the present study suggested a link between AGEs and the extent of inflammation; however, whether the changes in the inflammatory status contribute to the development of coronary artery disease in T2DM patients still require mechanistic studies.

In conclusion, the development of AS in T2DM is a complex process. In the present study, our results showed that the levels of AGEs may be correlated with the inflammatory status in T2DM patients with CAS. Our results may suggest a link between AGE levels and the extent of inflammation, which may contribute to the development of CAS in T2DM patients.
Acknowledgments: This study was supported by the Nanjing Medical University Science and Technology Development Fund Project (2017NJMUZD145) and the Nanjing Medical Science and Technology Development Project (YKK17269).

Conflict of interest: The authors state no conflict of interest.

References

[1] Nawaz MS, Shah KU, Khan TM, Rehman AU, Rashid HU, Mahmood S, et al. Evaluation of current trends and recent development in insulin therapy for management of diabetes mellitus. Diabetes Metab Syndr. 2017 Dec;11(Suppl 2):S833–9.

[2] Oktay AA, Akturk HK, Jahangir E. Diabetes mellitus and hypertension: a dual threat. Curr Opin Cardiol. 2016 Jul;31(4):402–9.

[3] Prystupiuk OM. Biomarkers and risk factors of cardiovascular system disease in diabetes mellitus type 2. Lik Sprava. 2013 Jan–Feb;1:73–7.

[4] Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):191–204.

[5] Pleskovic A, Letonja MS, Vujkovac AC, Nikolajevic Starcevic J, Gazdikova K, Caprnda M, et al. C-reactive protein as a marker of progression of carotid atherosclerosis in subjects with type 2 diabetes mellitus. Vasa. 2017 May;46(3):187–92.

[6] Willett P, Thompson SG, Agewall S, Bergstrom G, Bickel H, Catapano AL, et al. Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2016 Jan;23(2):194–205.

[7] Bansal S, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients. Gene. 2013 Sep 10;526(2):325–30.

[8] Chen Y, Wu Y, Gan X, Liu K, Lv X, Shen H, et al. Iridoid glycoside from Coriandr officinalis ameliorated diabetes mellitus-induced testicular damage in male rats: involvement of suppression of the AGEs/RAGE/p38 MAPK signaling pathway. J Ethnopharmacol. 2016 Dec 24;194:850–60.

[9] Xing Y, Ji Q, Li X, Ming J, Zhang N, Zha D, et al. Asiaticoside protects cochlear hair cells from high glucose-induced oxidative stress via suppressing AGEs/RAGE/NF-kappaB pathway. Biomed Pharmacother. 2017 Feb;86:531–6.

[10] Wu T, Chen X, Wang Y, Xiao H, Peng Y, Lin L, et al. Aortic plaque-targeted androgenopholide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammation. Nanomedicine. 2018 Oct;14(7):2215–26.

[11] Yamagishi SI, Sotokawauchi A, Matsui T. Pathological role of advanced glycation end products (AGEs) and their receptor axis in atrial fibrillation. Mini Rev Med Chem. 2019;19(13):1040–8.

[12] de Boer OJ, Becker AE, van der Wal AC. T lymphocytes in atherogenesis-functional aspects and antigenic repertoire. Cardiovasc Res. 2003 Oct 15;60(1):78–86.

[13] Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun. 2010;2(4):325–33.

[14] Kassem KM, Ali M, Rhaebe NE. Interleukin 4: its role in hypertension, atherosclerosis, valvular, and nonvalvular cardiovascular diseases. J Cardiovasc Pharmacol Ther. 2019 Aug 11;25:1074248419868699.

[15] Kaneko R, Sawada S, Tokita A, Honkura R, Tamura N, Kodama S, et al. Serum cystatin C level is associated with carotid arterial wall elasticity in subjects with type 2 diabetes mellitus: a potential marker of early-stage atherosclerosis. Diabetes Res Clin Prac. 2018 May;139:43–51.

[16] Jiang F, Wang J, Zhang R, Chen M, Peng D, Sun X, et al. Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in patients with type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 May;42(5):444–50.

[17] Xu H, Wang Z, Wang Y, Hu S, Liu N. Biodistribution and elimination study of fluorine-18 labeled Npsilon-carboxy-methyl-lysine following intrastraga and intravenous administration. PLoS One. 2013;8(3):e57897.

[18] Kurt A, Andican G, Siva ZO, Andican A, Burca G. The effects of n-3 long-chain polysaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus. J Physiol Biochem. 2016 Dec;72(4):679–87.

[19] Li Y, Liu S, Zhang Z, Xu Q, Xie F, Wang J, et al. RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation. PLoS One. 2012;7(4):e35016.

[20] Rasool M, Malik A, Butt TT, Ashraf MAB, Rasool R, Zahid A, et al. Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases. Saudi J Biol Sci. 2019 Feb;26(2):334–9.

[21] Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med. 1993 Dec 1;178(6):2165–72.

[22] Charemtanakul W, Fabros Jr D. Saponin Quil A up-regulates type I interferon-regulated gene and type I and II interferon expressions which are suppressed by porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol. 2018 Jan;195:76–83.

[23] Lopez P, Rodriguez-Carrio J, Martinez-Zapico A, Perez-Alvarez AI, Benavente L, Caminal-Montero L, et al. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17 + T cells in SLE patients with a pro-inflammatory lipid profile. Rheumatol. 2019 Jul 13;59(2):407–17.

[24] Cho JH, Kim MJ, Kim KJ, Kim JR. POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) inhibits endothelial cell senescence through a p53 dependent pathway. Cell Death Differ. 2012 Apr;19(4):703–12.

[25] Engelbertsen D, Autio A, Verwilligen RAG, Depuydt MAC, Newton G, Rattik S, et al. Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. Sci Rep. 2019 Jul 23;9(1):10608.
[26] Bash LD, White K, Patel MD, Liu J, Mavros P, Mahaffey KW. Cardiovascular risk factors and secondary events among acute and chronic stable myocardial infarction patients: findings from a managed care database. Cardiol Ther. 2019 Aug 20;8(2):329–43.

[27] Huang Y, Hu H, Liu L, Ye J, Wang Z, Que B, et al. Interleukin-12p35 deficiency reverses the Th1/Th2 imbalance, aggravates the Th17/Treg imbalance, and ameliorates atherosclerosis in ApoE−/- mice. Mediat Inflamm. 2019;2019:3152040.

[28] Naslund U, Lundgren A, Vanoli D, Norberg M. Is intima-media thickness a predictor for cardiovascular risk? – Authors’ reply. Lancet. 2019 Aug 3;394(10196):381.

[29] Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018 Nov 23;24(1):59.
Appendix

**Table A1:** Clinical parameters of the recruited subjects

| Parameters               | NC              | T2DM             | P    |
|--------------------------|-----------------|------------------|------|
| Age (years)              | 65.6 ± 3.1      | 64.7 ± 3.9       | >0.05|
| BMI (kg/m²)              | 24.3 ± 2.6      | 27.6 ± 3.2       | <0.05|
| Triglycerides (mg/dL)    | 111.7 ± 42.3    | 123.7 ± 35.6     | >0.05|
| Total cholesterol (mg/dL)| 163.7 ± 32.3    | 156.5 ± 38.9     | >0.05|
| HDL cholesterol (mg/dL)  | 41.2 ± 9.9      | 44.1 ± 11.4      | >0.05|
| LDL cholesterol (mg/dL)  | 104.8 ± 28.9    | 94.9 ± 21.7      | >0.05|
| Glycaemia (mg/dL)        | 92.6 ± 10.2     | 151.4 ± 21.1     | <0.05|
| HbA1c (%)                | 6.1 ± 0.4       | 7.4 ± 0.7        | <0.05|